PRPF6

Across TCGA pan-cancer cohorts, PRPF6 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PRPF6 data layer compared with 21 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PRPF6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRPF6 expression acts as an unfavorable survival marker, although some lineages such as COAD and LUAD show a favorable association.

CCRCC, COAD, and LUAD are the cancer types where PRPF6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.572	0.935	<.001	45	view →
COAD	DFS	Median	All	1.000	0.923	.019	18	view →
LUAD	OS	Quartile	III,IV	0.990	0.421	.026	18	view →
PDAC	DFS	Quartile	All	0.295	0.558	.012	8	view →
GBM	DFS	Quartile	All	0.537	0.324	.011	2	view →
HNSC	OS	Tertile	All	0.799	0.919	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PRPF6–CCRCC (DFS)

Open the CCRCC breakdown →